Decibel Therapeutics IncDecibel Therapeutics Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

Check the bottom of the page for potential risks for Decibel Therapeutics Inc based on industry, location and marketcap. This page contains a zero-cost E,S&G analysis covering Decibel Therapeutics Inc. The report of Decibel Therapeutics Inc leverages intelligence from across the internet as well as from public filings by Decibel Therapeutics Inc.

Decibel Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.9; made up of an environmental score of 2.0, social score of 4.0 and governance score of 5.7.

SDG Transparency Score for Decibel Therapeutics Inc 

3.9

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Decibel Therapeutics Inc 
2.0

Environmental

4.0

Social

5.7

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
1443XSpray Pharma AB (publ)
4.0
High
1443Zhong Yuan Bio-Technology Holdings Ltd
4.0
High
.........
1476Decibel Therapeutics Inc
3.9
Medium
1476Anebulo Pharmaceuticals Inc
3.9
Medium
1476Anhui Sunhere Pharmaceutical Excipients Co Ltd
3.9
Medium
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Decibel Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc offer flexible work?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Decibel Therapeutics Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose water use targets?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Decibel Therapeutics Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Decibel Therapeutics Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Decibel Therapeutics Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose its waste policy?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose energy use targets?

LockedSign up for free to unlock

Does Decibel Therapeutics Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Decibel Therapeutics Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Decibel Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.

Sorry!

Failed to process!